The Anti‐Inflammatory Effects of Liraglutide in Equine Inflammatory Joint Models
Journal of Orthopaedic Research · 2025
DOI: 10.1002/jor.26050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Orthopaedic Research, 2025. Verfasst von Ann-Sofie Scheike und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Liraglutide, Synovitis, Anti-Inflammatory Agents, Horse Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This project has received funding from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and innovation program..
Abstract (Originalsprache)
This study investigates the anti‐inflammatory properties of liraglutide, a glucagon‐like peptide 1 receptor agonists, in equine in vitro models and in an in vivo acute synovitis model in Shetland ponies. The anti‐inflammatory effect of liraglutide was assessed by measuring concentrations of inflammatory biomarker C‐C Motif Chemokine Ligand 2 (CCL2) in culture media of equine whole blood, peripheral blood mononuclear cells (PBMCs), chondrocytes, and synoviocytes, with or without lipopolysaccharide (LPS) or interleukin‐1β. In the in vivo experiment, acute synovitis was bilaterally induced with 0.25 ng LPS in the intercarpal joints of seven healthy Shetland ponies. The ponies were subsequently treated with either 6 mg liraglutide or a placebo as a paired control in each joint. The impact of liraglutide on biomarkers associated with inflammation (including white blood cell count, total protein, CCL2, and bradykinin) and cartilage metabolism (such as glycosaminoglycans, general matrix metalloproteinase activity, carboxypropeptide type II collagen, and collagen‐cleavage neoepitope of type II collagen) was assessed across serial synovial fluid samples. Liraglutide was found to have an anti‐inflammatory effect by reducing CCL2 concentrations in culture media of whole blood, PBMCs, chondrocytes, and synoviocytes. In contrast, no significant differences in synovial fluid inflammatory nor cartilage metabolism biomarker levels were found between joints treated with LPS and 6 mg liraglutide, versus LPS and placebo. In conclusion, liraglutide demonstrates the potential to attenuate inflammatory processes in joint cells. Additional research is necessary to validate its efficacy within the complex milieu of an inflamed joint.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
- 4Moving Biotech, Lille, France.
- INSERM CRSA, AP-HP Saint-Antoine Hospital, Sorbonne University, Paris, France.
ORCID-Profile: Ann-Sofie Scheike, Marianna Andriana Tryfonidou
Förderung
- This project has received funding from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and innovation program.
Zitieren
APA
Scheike, A. S., Plomp, S., Fugazzola, M. C., Meurot, C., Berenbaum, F., van Weeren, P. R., Tryfonidou, M. A., & von Hegedus, J. H. (2025). The Anti‐Inflammatory Effects of Liraglutide in Equine Inflammatory Joint Models. Journal of Orthopaedic Research. https://doi.org/10.1002/jor.26050
Vancouver
Scheike AS, Plomp S, Fugazzola MC, Meurot C, Berenbaum F, van Weeren PR, et al. The Anti‐Inflammatory Effects of Liraglutide in Equine Inflammatory Joint Models. Journal of Orthopaedic Research. 2025. doi:10.1002/jor.26050
BibTeX
@article{Scheike2025,
author = {Scheike, Ann-Sofie and Plomp, Saskia and Fugazzola, Maria Carlotta and Meurot, Coralie and Berenbaum, Francis and van Weeren, Paul René and Tryfonidou, Marianna Andriana and von Hegedus, Johannes Hendrick},
title = {The Anti‐Inflammatory Effects of Liraglutide in Equine Inflammatory Joint Models},
journal = {Journal of Orthopaedic Research},
year = {2025},
doi = {10.1002/jor.26050}
}
EUVIMED